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Background: Saponins of several herbs are known to induce apoptosis in many cancer cells. The present study
aimed to investigate the growth inhibitory effect of Paris saponin VII (PS VII), a kind of steroidal saponins from
Chonglou (Rhizoma Paridis Chonglou), on the human cervical cancer cell line Hela and the relative molecular
mechanisms.
Methods: Hela cells were exposed to different concentrations of PS VII (1 to 100 μM). Inhibition of cell proliferation
was measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and 5-ethynyl-2′-deoxyuridine
(EdU) assays. The amount of apoptotic cells was evaluated by flow cytometric analysis. And the protein level of
cleaved caspase-3, cleaved caspase-9, Bax, and Bcl-2 was evaluated by Western blot.
Results: The half maximal inhibitory concentration (IC50) value of PS VII for the growth inhibition of Hela cells was
2.62 ± 0.11 μM. PS VII increased the expression of caspase-3, caspase-9, and Bax while decreased that of Bcl-2,
suggesting that PS VII may induce apoptosis through intrinsic apoptotic ways.
Conclusions: These data indicate that PS VII has the potential for the treatment of cervical cancer.
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Cervical cancer is the third most common type of cancer
in women worldwide, and a leading cause of cancer-related
mortality, with an estimated 275,000 deaths in 2008 [1].
Despite considerable advances in surgical techniques and
neoadjuvant chemotherapy, the survival rate of cervical
cancer is still not remarkably improved. Platinum-based
anticancer agents, represented by cisplatin, have therapeutic
properties for patients with cervical cancer; however, toxic-
ities, including myelosuppression, leukopenia, ototoxicity,
neurotoxicity, and nephrotoxicity [2,3], may limit their
long-term use. Therefore, it is required to develop new
drugs with a more specific effect and low toxicity.
Natural products have been shown to be excellent and
reliable sources for the pharmaceutical development of an-
ticancer drugs [4]. Chonglou (Rhizoma Paridis Chonglou)
is the root of Paris polyphylla. Phytochemical and pharma-
cological studies suggest that Chonglou has a wide range* Correspondence: 1411833615@qq.com
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regulatory, and cardiovascular effects [5]. It has been
applied in the treatment of malignant lymphomas, lung
cancer, nasopharyngeal carcinoma, brain tumors, and
digestive system carcinomas. Polyphyllin and extracts from
Chonglou show good antitumor effects in vitro, through in-
ducing apoptosis, affecting cell cycle distribution, inhibiting
angiogenesis, and regulating the immune function [6,7].
In the current study, we investigated the mechanism
underlying the cytotoxic effects of a kind of steroidal sapo-
nins from Chonglou (Rhizoma Paridis Chonglou), namely,
Paris saponin VII (PS VII), and its antitumor properties
on Hela cell lines. The results indicated that PS VII inhib-
ited the growth of the cell effectively. It upregulated cleaved
caspase-3, cleaved caspase-9, and Bax expression in Hela
cells. These preclinical studies indicated that PS VII may
have potentials in the treatment of cervical cancer.Methods
Chemicals and reagents
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium brom-
ide (MTT), Hoechst 33342, and propidium iodide (PI) wereLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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was from Beyotime Institute of Biotechnology (Jiangsu,
China). Anti-cleaved caspase-3, cleaved caspase-9, Bcl-2,
and Bax antibodies were obtained from Cell Signaling
(Beverly, MA, USA). Anti-β-actin antibodies were obtained
from Santa Cruz Biotechnology (Santa Cruz, CA, USA). PS
VII (Figure 1) with a purity of >98% was purchased from
PureOne Biotechnology (Shanghai, China).
Cell culture
Hela, a human cervical cancer cell line, was obtained from
the American Type Culture Collection (ATCC; Manassas,
VA, USA) and maintained in DMEM medium supple-
mented with 10% fetal bovine serum, 100 U/ml penicillin,
and 100 U/ml streptomycin. The cells were maintained in
a humidified atmosphere at 37°C in 5% CO2.
Cell proliferation assays
Cell viability was determined by MTT and 5-ethynyl-2′-
deoxyuridine (EdU) assays. The Hela cells were seeded
at a density of 2 × 104 cells/well in 96-well plates full of
medium containing PS VII at various concentrations (1,
3, 10, 30, and 100 μM). After 24-h treatment, 20 μl of
MTT solution (0.5 mg/ml) was added into each well and
the mixture was incubated at 37°C for 4 h. The cells were
then washed thrice with phosphate-buffered saline (PBS),
and the formazan was resuspended in 150 μl DMSO. Ab-
sorbance was measured at 490 nm by using a Bio-Rad
ELISA reader (Hercules, CA, USA). Half maximal inhibi-
tory concentrations (IC50) of PS VII were determined by
curve fitting analyses using Prism software (GraphPad
Software, San Diego, CA, USA). For EdU assay, Hela cells
(1 × 105 cells/well) were seeded in 24-well plates. After
culture in a serum-free medium for 24 h, various concen-
trations of PS VII (0.8, 1.6, and 2.4 μM) were added and
the cells were kept for another 24 h. Cell viability was
determined using an EdU assay kit. Stained sections were
examined under a microscope (Nikon, Tokyo, Japan). All
experiments were repeated independently thrice.
Flow cytometric assays for annexin V
Hela cells were plated at a density of 5 × 106 per 10-cm2
dish and cultured with different concentrations of PS VIIFigure 1 The structure of Paris saponin VII (PS VII).for 24 h. A total of 1 × 106 to 3 × 106 cells were washed
with ice-cold PBS and resuspended in 1× binding buffer
[10 mM HEPES/NaOH (pH 7.4), 140 mM NaCl, 2.5 mM
CaCl2] at a concentration of 1 × 10
6 cells/ml. Five microli-
ters of annexin V-fluorescein isothiocyanate (FITC) solu-
tion (25 μg/ml) and 5 μl of dissolved PI (250 μg/ml) were
added to 100 μl of the cell suspensions. The cells were
then gently vortexed and incubated at room temperature
in the dark for 15 min. Then, 400 μl of ice-cold binding
buffer was added and mixed gently before the cell prepa-
rations were examined by flow cytometry (FACSCalibur,
Becton Dickinson, San Jose, CA, USA).Caspase-3 activity
Caspase-3 activity in Hela cells was detected using the
Caspase-3 Activity Assay Kit (Beyotime Institute of Bio-
technology, Jiangsu, China). The assay is based on the hy-
drolysis of the peptide substrate acetyl-Asp-Glu-Val-Asp
p-nitroanilide (Ac-DEVD-pNA) by caspase-3, resulting in
the release of a pNA moiety. Absorbance values were
measured at 405 nm. Results were adjusted to the total
protein content, and activity was expressed as nanomoles
of pNA per milligram of total protein.Western blot analysis
Hela cells were incubated with 0.8, 1.6, or 2.4 μM of PS
VII for 24 h. The cells were then harvested and resus-
pended in lysis buffer (Beyotime Institute of Biotechnol-
ogy, Jiangsu, China, plus the protease inhibitors leupeptin
10 μg/ml, aprotinin 10 μg/ml, and PMSF 0.1 mmol/l).
Protein lysates (30 μg) were electrophoresed on 15%
SDS polyacrylamide gels and transferred to nitrocellu-
lose membranes (Pall Corporation, Port Washington,
NY, USA) and blocked with Tris-buffered saline (TBS)
buffer containing 0.05% Tween-20 and 5% nonfat milk
for 2 h at room temperature. The membranes were
then incubated overnight at 4°C with various primary
antibodies, followed by HRP-conjugated secondary
antibodies. After washing the membranes thrice for 10
min in TBS buffer containing 0.05% Tween-20, the
immunoreactive bands were detected using the Immo-
bilon Western HRP Substrate (Millipore, Billerica, MA,
USA). The experiment was repeated independently three
times.Statistical analysis
Data were expressed as mean ± standard deviation
(SD). Statistical analyses were done by using the one-way
ANOVA test and Fisher’s least significant difference
(LSD) t test to compare the different groups. Probability
(P value) of less than 0.05 was considered to be statisti-
cally significant.
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PS VII inhibited the cell growth of Hela cells
The viability of Hela cells treated with PS VII at different
concentrations (1, 3, 10, 30, and 100 μM) for 24 h was
determined by MTT assay. As shown in Figure 2a, PS
VII decreased the cell viability rate in a concentration-
dependent manner. In comparison to the control
groups, treatment with PS VII at the concentrations of
3 and 10 μM decreased the survival rate of Hela cells
to 51.16% ± 0.58% and 14.57% ± 0.24%, while at the
concentrations of 50 and 100 μM, PS VII significantly
(P < 0.01) reduced the viability rate of Hela cells to
6.63% ± 0.26% and 3.45% ± 0.13%. The IC50 value
showed 2.62 ± 0.11 μM in Hela cells. To investigate
whether this effect was selective, a normal cervical epi-
thelial cell line, End1/E6E7, was treated with various
concentrations (1, 3, 10, 30, and 100 μM) of PS VII for
24 h. The results show that PS VII had no obvious
growth-inhibiting effect on End1/E6E7, even at the
highest concentration of 100 μM (Figure 2b). Based on
the IC50 value, in the following steps, PS VII at the
concentrations of 0.8, 1.6, and 2.4 μM was chosen to
treat Hela cells. Results of EdU assay (Figure 2c) also
showed that PS VII exhibited an obvious growth-
inhibiting effect on Hela cells.Figure 2 The effect of PS VII treatment on the growth of Hela and En
3, 10, 30, and 100 μM on Hela cells. Common logarithm values of the conc
Lg30 = 1.5, and Lg100 = 2.0. (b) The effect of PS VII at the concentrations o
End1/E6E7. (c) The effect of PS VII at the concentrations of 0.8, 1.6, and 2.4
assays. Red staining showed proliferative cells. Sections were counterstaine
magnification, ×200).PS VII induced cell apoptosis in Hela cells
To investigate whether the growth inhibition of PS VII
was caused by apoptosis, annexin V-FITC/PI assay was
used. The percentage of apoptotic cells (Q2 + Q4) in
Hela cells was 3.77% ± 0.91%. When exposed to 0.8, 1.6,
and 2.4 μM of PS VII for 24 h, the percentage increased
to 10.50% ± 2.12%, 17.37% ± 1.86%, and 38.60% ± 5.34%,
respectively (Figure 3a). The activity of caspase-3 was
also measured. As shown in Figure 3b, obvious activa-
tion of caspase-3 was observed in Hela cells treated
with PS VII, which seemed to be in a concentration-
dependent manner, whereas low caspase-3 activity was
detected in the control group. The decrease activity of
caspase-3 in the cells treated with PS VII was significantly
blocked by pretreatment of a general caspase inhibitor,
Z-VAD-FMK.
PS VII acted on the intrinsic apoptotic pathway
To search for the indication of mechanisms involved in
apoptosis, the expression of cleaved caspase-3, caspase-8,
and caspase-9 was evaluated. Compared with that in con-
trol cells, the expression of caspase-3 and caspase-9 signifi-
cantly increased in Hela cells (Figure 4) while caspase-8
had no significant change (data not shown) after being
treated with 0.8, 1.6, and 2.4 μM of PS VII for 24 h. Ind1/E6E7 cell lines. (a) The effect of PS VII at the concentrations of 1,
entrations were used as the X-axis. Lg1 = 0.0, Lg3 = 0.5, Lg10 = 1.0,
f 1, 3, 10, 30, and 100 μM on the normal cervical epithelial cell line
μM on Hela cells. Cell proliferation of Hela cells was evaluated by EdU
d with Hoechst (blue) to identify the orientation of nuclei (original
Figure 3 The effect of PS VII treatment on the apoptosis of Hela cells. (a) Annexin V analysis of Hela cells treated with PS VII at the concentrations
of 0.8, 1.6, and 2.4 μM for 24 h. PS VII treatment increased the percentages of annexin V+/PI− (right lower quadrant) and annexin V+/PI + (right upper
quadrant) cells. (b) Effect of PS VII on the caspase-3 activity of Hela cells. Data were the mean ± SD of three separate experiments. **P< 0.01 vs. control.
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while Bax expression increased. Furthermore, the decrease
in the levels of caspase-3 and caspase-9 in the cells treated
with PS VII was significantly blocked by pretreatment of a
general caspase inhibitor, Z-VAD-FMK (Figure 5). These
data suggested that PS VII induced cell apoptosis through
an intrinsic pathway depending on caspase activation.
Discussion
Chonglou (Rhizoma Paridis Chonglou) has been trad-
itionally used for the treatment of microbial infection,hemorrhage, menometrorrhagia, and venomous poison
[8-11]. The main bioactive ingredients of Chonglou are
the steroidal saponins. Phytochemical and pharmaco-
logical studies have further revealed a novel therapeutic
role as an anticancer agent for these steroid saponins [12].
However, evidence-based researches into the mechanism
underlying the cytotoxic effects of steroidal saponins are
still undefined.
In the current study, we found that PS VII, a kind of
steroidal saponins from Chonglou, could inhibit the
growth of Hela cells in a concentration-dependent manner.
Figure 4 The effect of PS VII treatment on apoptosis-related protein expression. PS VII increased cleaved caspase-3, cleaved
caspase-9, and Bax while decreased Bcl-2 expression in protein level in the Hela cells treated with 0.8, 1.6, or 2.4 μM PS VII for
24 h. ‘Quantity one’ of Bio-Rad and SPSS 17.0 were used to deal with the results of Western blot. *P < 0.05 vs. control; **P < 0.01
vs. control.
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inhibiting effect of PS VII was caused by apoptosis.
Apoptosis, which is characterized by membrane bleb-
bing, shrinkage of the cytoplasm and nucleus, and DNA
fragmentation [13], helps to keep tissue homeostasis by
eliminating potentially deleterious cells. Deregulated
apoptotic cell death would lead to diseases such as can-
cer. In cancer cells, the incidence of apoptosis and the
rate of cell proliferation are uncontrolled, which would
cause tumor invasion. Therefore, it will be a reasonable
way to induce cancer cells to undergo apoptosis by various
anticancer agents.Results of flow cytometric analysis showed that PS VII
increased the apoptosis of Hela cells in a concentration-
dependent manner.
Mammalian cells undergo apoptosis mainly through
two ways: the death receptor-mediated or extrinsic pathway
and the mitochondrial-mediated or intrinsic pathway [14].
Caspases, a family of cysteine proteases, are central regula-
tors of apoptosis. Caspase-8 is involved in the extrinsic and
caspase-9 in the intrinsic pathway. After activation, they
would cleave and activate downstream effectors such as
caspase-3, which subsequently cleave cytoskeletal and
nuclear proteins [15,16]. Results of caspase-3 activity
Figure 5 Activation of caspase-3 and caspase-9 after treatment with PS VII. Cell lysates were prepared after treatment with drugs for 24 h
and then analyzed by Western blot with caspase-3 or caspase-9 antibody. The protein level of cleaved caspase-3 and caspase-9 was increased by
PS VII treatment. However, the activation of caspase-3 and caspase-9 was minimized after pretreatment of a pan-caspase inhibitor (Z-VAD-FMK).
‘Quantity one’ of Bio-Rad and SPSS 17.0 were used to deal with the results of Western blot. *P < 0.05 vs. control; **P < 0.01 vs. control.
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caspase-3 activity in Hela cells. And these effects seemed
to be concentration dependent. Western blot analysis
demonstrated that PS VII treatments caused increased
cleaved caspase-3 and caspase-9 expression, but had no
significant effect on cleaved caspase-8 expression. The
cleavage of caspases was prevented by pretreatment of
Hela cells with a pan-caspase inhibitor, Z-VAD-FMK.
These findings suggest that PS VII induced the apoptosis
of Hela cells through an intrinsic way involving caspase
activation.
This was proved by decreased Bcl-2 expression and in-
creased Bax expression. The Bcl-2 protein family, which
plays an important role in the intrinsic pathway, is divided
into two functional subfamilies: pro-apoptotic proteins (Bax
and Bid) and anti-apoptotic proteins (Bcl-2 and Bcl-xL).
The ratio of Bax/Bcl-2 appears to be a critical determinant
of a cell’s threshold for undergoing apoptosis. Results ob-
tained above were from in vitro experiments. In the next
step, we will assess the effect of PS VII in vivo and find the
possible mechanisms by using xenograft models.Conclusions
In brief, the results reported herein demonstrated that
PS VII inhibited the growth and induced the apoptosis
of Hela cells effectively. One of the possible mechanisms
involved is that PS VII triggered cell apoptosis via an
intrinsic pathway depending on caspase activation. The
precise signaling pathway remains to be further inves-
tigated. However, these data may provide an approach
to treat cervical cancer.
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